Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. Treasury yields fell and oil plunged after reports of a U.S.-Iran ceasefire, easing risk premia and pressuring energy-linked assets.
  • AMD shares fell about 8% amid a semiconductor selloff driven by AI spending concerns and pre-earnings caution.
  • NVIDIA slipped 4.6% as traders flagged the pullback as a potential entry point into core AI hardware exposure.
  • ServiceNow jumped about 5.5% after beating Q2 results and raising subscription revenue guidance, strengthening the AI-driven enterprise software narrative.
  • JBS shares rallied after a USDA projection of higher beef prices, lifting inflation-linked upside for meat processors.
  • UK Prime Minister Andy Burnham said stamp duty will remain unchanged in the next budget, removing an immediate property tax change.

Latest Articles

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
May 21, 2026
Maya Rios
Press Releases

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Akari Therapeutics announced positive preclinical data demonstrating that their lead antibody drug conjugate (ADC), AKTX-101, synergizes with KRAS inhibitors (including adagrasib) to enhance cytotoxic activity against KRAS-mutated pancreatic cancer models. Unlike traditional ADCs, AKTX-101 uses a novel RNA spliceosome modulating payload (PH1) that …

AKTX
Navient declares second quarter common stock dividend
May 21, 2026
Marcus Reed
Press Releases

Navient declares second quarter common stock dividend

Navient Corporation declared a second quarter 2026 dividend of $0.16 per common share, payable on June 19, 2026, to shareholders of record as of June 5, 2026. The company continues to focus on responsible lending, refinancing options, and financial services through its Earnest business unit.

NAVI
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
May 21, 2026
Hana Yamamoto
Press Releases

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology announced a webcast on June 3, 2026, to discuss updated Phase 2 clinical trial data of Onvansertib, their PLK1 inhibitor drug candidate combined with standard-of-care treatments for first-line RAS-mutated metastatic colorectal cancer. Updated results show dose-dependent improvements in overall response rate and progression-free sur…

CRDF
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
Jordan Park
Press Releases

Legend Biotech Announces Presentations at ASCO 2026

Legend Biotech announced multiple presentations at the ASCO 2026 meeting, including preliminary Phase 1 results for LB2102, a DLL3-targeted CAR-T therapy showing early activity in solid tumors like small cell lung cancer. Additional data on CARVYKTI (ciltacabtagene autoleucel) reinforces its efficacy in multiple myeloma, supporting ongoing studies …

LEGN
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Hana Yamamoto
Press Releases

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Olema Oncology announced encouraging preliminary results from the Phase 1 clinical trial of OP-3136, a selective KAT6 inhibitor, showing tolerability and anti-tumor activity across multiple advanced solid tumors. The data support continued development of OP-3136 both as monotherapy and combined with current endocrine therapies in metastatic breast …

OLMA
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026
Derek Hwang
Press Releases

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics announced encouraging Phase 1 trial results of CTX-8371, a novel bispecific antibody targeting PD-1 and PD-L1, demonstrating deep and durable responses in patients with advanced malignancies resistant to prior immune checkpoint inhibitors. The drug showed clinical activity in triple-negative breast cancer, Hodgkin lymphoma, and…

CMPX
NVIDIA Announces Upcoming Events for Financial Community
May 21, 2026
Hana Yamamoto
Press Releases

NVIDIA Announces Upcoming Events for Financial Community

NVIDIA has announced its participation in two upcoming major financial community events: the TD Cowen 54th Annual Technology, Media, & Telecom Conference on May 28, 2026, and the BofA Global Technology Conference on June 4, 2026. The company will webcast these financial presentations live, providing investors and industry stakeholders with updates …

NVDA
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
Nina Shah
Press Releases

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Corporation announced a 17.3-month median overall survival in a Phase 2a trial of atebimetinib combined with chemotherapy in first-line metastatic pancreatic cancer patients. The treatment showed a tolerable safety profile with only chemotherapy-related Grade 3 or higher adverse events observed in 10% or more of patients. The company wi…

IMRX
TruGolf Reports First Quarter 2026 Results
May 21, 2026
Derek Hwang
Press Releases

TruGolf Reports First Quarter 2026 Results

TruGolf Holdings reported a modest revenue decline to $5.0 million in Q1 2026 compared to $5.2 million in Q1 2025, with a slight drop in golf simulator sales offset by increased software contracts. The company reduced its net loss to $1.4 million from $2.7 million in the prior year quarter, driven by lower operating expenses and interest costs. Tru…

TRUG
Director Transactions and Strong Earnings Signal for Steven Madden Ltd.
May 21, 2026
Sofia Navarro
Insider Trading

Director Transactions and Strong Earnings Signal for Steven Madden Ltd.

A review of recent filings shows a director at STEVEN MADDEN, LTD. engaging in both stock sales and restricted stock grants. This activity was reported against the backdrop of the company's strong first-quarter 2026 earnings. The firm exceeded revenue expectations with $653.1 million and posted an EPS of $0.45, leading Williams Trading to raise its…

Canada mandates 15% Canadian-content spending for global streaming services
May 21, 2026
Priya Menon
Stock Markets

Canada mandates 15% Canadian-content spending for global streaming services

The Canadian Radio-television and Telecommunications Commission has finalized rules under the Online Streaming Act requiring online streaming platforms, including Netflix and Spotify, to allocate 15% of their domestic annual revenues to Canadian content. Traditional broadcasters face a lowered minimum contribution of 25% of domestic revenues. The r…

U.S. Attorney Drops Charges Linked to Broadview Immigration Protest
May 21, 2026
Avery Klein
World

U.S. Attorney Drops Charges Linked to Broadview Immigration Protest

The U.S. Attorney's Office in Chicago has dismissed all remaining criminal charges against four individuals who were indicted following protests outside the federal immigration holding facility in Broadview, Illinois. The move, announced in federal court, eliminates misdemeanor impediment charges after an earlier felony conspiracy count was already…

Trump Announces Additional 5,000 U.S. Troops to Be Sent to Poland
May 21, 2026
Nina Shah
World

Trump Announces Additional 5,000 U.S. Troops to Be Sent to Poland

On May 21, President Donald Trump announced that the United States will send 5,000 more troops to Poland, attributing the decision to his relationship with Poland's newly elected president, Karol Nawrocki. The declaration comes after U.S. Vice President JD Vance had said a deployment to Poland was delayed and amid a broader U.S. review of its milit…

Executive Selling Activity at Venture Global Signals Market Valuation Concerns Amid Strong Fundamentals
May 21, 2026
Hana Yamamoto
Insider Trading

Executive Selling Activity at Venture Global Signals Market Valuation Concerns Amid Strong Fundamentals

Venture Global's Chief Operating Officer, Brian Cothran, executed multiple transactions between May 19 and May 21, 2026, selling approximately $9.2 million worth of company shares. These sales followed the exercise of stock options for a total acquisition value of $726,236. The activity took place while Venture Global (NASDAQ: VG) shares maintain h…

CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman
May 21, 2026
Avery Klein
Press Releases

CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman

CVB Financial Corp., a top-performing California-based bank holding company with over $20 billion in assets, announced a leadership transition following its annual meeting. George A. Borba Jr., a long-serving director and Vice Chairman, has been appointed Chairman of the Board, succeeding Hal W. Oswalt who transitions to Vice Chairman. The company …

CVBF